Literature DB >> 4038549

Synergic effect of cisplatin, Adriamycin, and cyclophosphamide combination chemotherapy and radiotherapy in non-small cell lung cancer.

S Yoneda, T Honma, S Yoshida, K Y Min, Y Noguchi, M Sakura.   

Abstract

61 patients with inoperable non-small cell lung cancer were treated by combination chemotherapy with cisplatin, Adriamycin and cyclophosphamide. 23 patients received radiotherapy in addition to the chemotherapy. 49 out of 55 adequately treated patients were evaluable for tumor response. Of 29 patients who received chemotherapy alone, 6 (21%) achieved partial responses. Of 20 patients who received combined chemotherapy and radiotherapy, 16 (80%) achieved complete or partial responses. The median survival time was 18 months for 22 patients treated with combined therapies.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4038549     DOI: 10.1159/000225991

Source DB:  PubMed          Journal:  Oncology        ISSN: 0030-2414            Impact factor:   2.935


  2 in total

Review 1.  Combination chemotherapy for advanced adenocarcinoma of the lung. A review.

Authors:  J B Sørensen; H H Hansen
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

2.  The growth-inhibitory effect of 4-hydroperoxycyclophosphamide against human non-small cell lung carcinoma is enhanced by low-dose difluoromethylornithine.

Authors:  D C Tsai; G D Luk
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.